UNASSIGNED:提出了全球肢体解剖分期系统(GLASS)来评估手术复杂性和技术故障率,并对慢性威胁肢体缺血(CLTI)的解剖模式进行分层。然而,需要更多的证据来验证GLASS在接受药物涂层球囊(DCBs)的CLTI患者血管内治疗后的分期结局.这项研究旨在评估GLASS在预测DCB治疗的CLTI患者预后中的作用。
未经评估:此多中心,回顾性队列研究纳入2016年7月至2019年6月接受DCBs治疗的CLTI患者.为每个肢体分配GLASS阶段。基于肢体的通畅率(LBP),临床驱动靶病变血运重建(CD-TLR)率,临床改善,在12个月的随访中,对GLASS各阶段的安全性终点进行了分析和比较.使用Cox回归分析确定LBP丢失的危险因素。
未经评估:共纳入90条肢体,其中55例(61.1%)有孤立的股pop病变,35例(38.9%)有股pop和股下病变。四肢,17(18.9%),12(13.3%),61人(67.8%)被分配到GLASS第一阶段,II,III,分别。Kaplan-Meier对12个月LBP的估计为65.4%,在不同阶段之间没有发现差异(I阶段81.1%;II阶段85.2%;III阶段54.4%;P=0.080)。III期LBP低于I和II期(I和II期83.5%;III期54.4%;P=0.027)。对于不同阶段中的CD-TLR的自由率,发现了类似的结果。随访时踝肱指数值从0.42±0.29提高到0.78±0.35(P<0.001)。死亡率,任何截肢,两组之间的主要截肢手术相似。GLASSIII期和冠心病被确定为12个月时LBP丧失的独立危险因素。
UNASSIGNED:GLASSIII期的1年LBP和无CD-TLR率低于I期和II期。GLASS分类可以预测DCB治疗股pop病变的CLTI患者的预后。
UNASSIGNED: The Global Limb Anatomic Staging System (GLASS) was proposed to assess the procedural complexity and technical failure rate and stratify the anatomic pattern of chronic limb-threatening ischemia (CLTI). However, more evidence is needed to validate the GLASS in staging outcomes after endovascular therapy in patients with CLTI treated with drug-coated balloons (DCBs). This study aims to evaluate the role of the GLASS in predicting outcomes of CLTI patients treated with DCBs.
UNASSIGNED: This multicenter, retrospective cohort study enrolled patients with CLTI treated with DCBs from July 2016 to June 2019. GLASS stages were assigned for every limb. The limb-based patency (LBP) rate, clinically driven target lesion revascularization (CD-TLR) rate, clinical improvement, and safety endpoints were analyzed and compared across the GLASS stages over 12 months of follow-up. Risk factors for the loss of LBP were identified using Cox regression analysis.
UNASSIGNED: A total of 90 limbs were enrolled, with 55 (61.1%) having isolated femoropopliteal lesions and 35 (38.9%) having femoropopliteal and infrapopliteal lesions. Of the limbs, 17 (18.9%), 12 (13.3%), and 61 (67.8%) were assigned to GLASS stages I, II, and III, respectively. The Kaplan-Meier estimate of the 12-month LBP was 65.4%, and no difference was found among the different stages (stage I 81.1%; stage II 85.2%; stage III 54.4%; P=0.080). The LBP was lower in stage III than in stages I and II combined (stage I and II 83.5%; stage III 54.4%; P=0.027). Similar results were found for the freedom from CD-TLR rates among the different stages. The ankle-brachial index values improved from 0.42±0.29 to 0.78±0.35 at follow-up (P<0.001). The rates of mortality, any amputation, and major amputation were similar among the groups. GLASS stage III and coronary heart disease were identified as independent risk factors for the loss of LBP at 12 months.
UNASSIGNED: The 1-year LBP and freedom from CD-TLR rates were lower in GLASS stage III than in stages I and II. The GLASS classification could predict the outcomes of CLTI patients with femoropopliteal lesions treated with DCB.